Nonpharmacologic and pharmacologic management of weight gain

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 21, 1999, Pages 31-36

  Greenberg, Isaac ^a,b   Chan, Samuel ^a   Blackburn, George L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; PSYCHOTROPIC AGENT; SIBUTRAMINE;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET THERAPY; HUMAN; HYPERTENSION; OBESITY; OSTEOARTHRITIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN;

EID: 0032693666     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993;270:2207-2212
2. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-1606
3. Bray GA. Complications of obesity. Ann Intern Med 1985;103:1052-1062
4. Hamwi GJ. Therapy: changing dietary concepts. In: Danowski TS, ed. Diabetes Mellitus: Diagnosis and Treatment. New York, NY: American Diabetes Association; 1964:73-78
5. Kanders BS, Forse RA, Blackburn GL. Methods in obesity. In: Rakel RE, ed. Conn's Current Therapy. Philadelphia, Pa: WB Saunders; 1991: 524-531
6. Blackburn GL, Dwyer J, Glanders WE, et al. Report of the American Institute of Nutrition (AIN) Steering Committee on Healthy Weight. J Nutr 1994;124:2240-2243
7. Scientific Status Summary. Human obesity. Food Technol 1994;48: 127-138
8. Advisory Committee on the Dietary Guidelines for Americans. Report on the dietary guidelines for Americans. Bethesda, Md: US Dept of Agriculture, Agricultural Research Service; 1995
9. National Institutes of Health, National Heart, Lung, and Blood Institute. The practical guide to identification, evaluation and treatment of over-weight and obesity in adults: the evidence report. Obes Res 1998;6: 51S-210S.
10. Foster GD, Wadden TA, Vogt RA, et al. What is a reasonable weight loss? Patients' expectations and evaluation of obesity treatment outcomes. J Consult Clin Psychol 1997;65:79-85
11. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994;236(suppl 736):13-22
12. Torgerson JS. Lindroos A, Sjostrom CD, et al. Are elevated amino transferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes Res 1997;5:105-114
13. Blackburn GL. Effect of degree of weight loss on health benefits. Obes Res 1995;333:677-685
14. Thomas PR, ed. Weighing the Options: Criteria for Evaluating Weight Management Programs. Washington, DC: National Academy Press; 1995: 91-93
15. Foreyt JP, Goodrick KG. Evidence for success of behavior modification in weight loss and control. Ann Intern Med 1993;119(7, part 2):698-701
16. Blair SN. Evidence for success of exercise in weight loss and control. Ann Intern Med 1993;119(7, part 2):702-706
17. Wadden TA. Evidence for success of caloric restriction in weight loss and control: summary data from clinical research studies. In: Scannell K, Dich SM, eds. Methods for Voluntary Weight Loss and Control. Bethesda, Md: US Dept of Health and Human Services; 1992:64-74
18. Blackburn GL. Comparison of medically supervised and unsupervised approaches to weight loss and control. Ann Intern Med 1993;119(7, part 2):714-718
19. Blackburn GL, Bistrian BR, Flatt JP. Role of a protein modified fast in comprehensive weight reduction program. In: Howard AN, ed. Recent Advances in Obesity Research: Proceedings of the First International Congress on Obesity. London, England: Newman; 1975:279-284
20. Kanders BS, Blackburn GL. Very-low-calorie diets for the treatment of obesity. In: Blackburn GL, Kanders BS, eds. Obesity Pathophysiology, Psychology and Treatment. New York, NY: Chapman & Hall; 1994: 197-216
21. Hoffer LJ, Bistrian BR, Blackburn GL. Composition of weight loss resulting from very-low-calorie protein-only and mixed diets. In: Blackburn GL, Bray GA, eds. Management of Obesity by Severe Calorie Restriction. Littleton, Mass: PSG Publishing Co; 1985
22. Ditschuneit HH, Flechtner-Mors M, Johnson TD, et al. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr 1999;69:198-204
23. Bray GA. Use and abuse of appetite suppressant drugs in the treatment of obesity. Ann Intern Med 1993;119:707-713
24. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;227:581-588
25. Bray GA. Obesity: a time bomb to be defused. Lancet 1998;352:160-161
26. Bray GA, Ryan DH, Gordon D, et al. Double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-270
27. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine-dose response and long-term efficacy in weight loss, a double-blind study. Int J Obes 1994;18(suppl 2):60-64
28. Lean ME. Sibutramine: a review for clinical efficacy. Int J Obes Relat Metab Disord 1997;21(suppl 1):S30-S36
29. Weintraub M, Rubio A, Golik A, et al. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-337
30. Stock MJ. Sibutramine: a review of the pharmacology of a novel antiobesity agent. Int J Obes Relat Metab Disord 1997;21(suppl 1):S25-S29
31. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(suppl 3):S12-S13
32. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998;54:125-132
33. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight gain in obese patients. Lancet 1998;352:167-172
34. McNeely W, Benfield P. Orlistat. Drugs 1998;56:241-249
35. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 2-year randomized double-blind study. Diabetes Care 1998;21:1288-1294
36. Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 1998;22:619-623
37. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996;36:152-159
38. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996;36:647-653
39. NIH Consensus Development Conference Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991;115:956-961
40. Macgregor AM, Rand CS. Gastric surgery in morbid obesity. Arch Surg 1993;128:1153-1157
41. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? an operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-350
42. Foley EF, Benotti PN, Borlase BC, et al. Impact of gastric restrictive surgery on hypertension in the morbidly obese. Am J Surg 1992;163:294-297